Genetic Basis of Inherited Bone Marrow Failure Syndromes by Yigal Dror
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
18 
Genetic Basis of  
Inherited Bone Marrow Failure Syndromes  
Yigal Dror 
The Hospital for Sick Children and The University of Toronto, Toronto 
 Canada 
1. Introduction 
Inherited bone marrow failure syndromes (IBMFSs) are multi-system disorders with 
varying degrees of defective production of erythrocytes, granulocytes and platelets in the 
bone marrow, leading to single-lineage or multilineage cytopenia (Table 1).(Dror 2006) The 
term IBMFSs is reserved for disorders that are caused by mutations, which are either 
inherited from the parents or occurred de-novo.(Alter 2003; Dokal and Vulliamy 2008) 
Based on the transmission patterns of the diseases (e.g. dominant or recessive autosomal or 
X-linked) and the segregation of known IBMFSs genes within multiplex families, the 
IBMFSs are considered as monogenic (Mendelian) diseases.(Alter 2003; Shimamura 2006; 
Dokal and Vulliamy 2008) The incidence of establishing a diagnosis of IBMFSs is about two 
new cases per a general population of million people per year and 65 cases per 106 child 
births.(Tsangaris, Klaassen et al. 2011) 
In some IBMFSs (e.g. Fanconi anemia) pancytopenia (>2 lineages affected) usually evolves. 
In others, one lineage is predominantly affected (e.g. neutropenia in Kostmann/severe 
congenital neutropenia, anemia in Diamond Blackfan anemia or thrombocytopenia in 
thrombocytopenia absent radii).  
The bone marrow failure often causes substantial morbidity and mortality, and many 
patients require life-long blood transfusions, treatment for infections, growth factors and 
hematopoietic stem cell transplantation (HSCT). Due to hematological and non-
hematological problems, high risk of cancer and major treatment-related toxicity, the life 
expectancy of the patients is substantially reduced.(Dror 2006; Alter 2007)  
IBMFSs have both unique and common features. The clinical manifestations could not 
always discriminate between the various IBMFSs or between IBMFSs from acquired bone 
marrow failure syndromes. The associations of bone marrow failure with either congenital 
malformations or presentation during the first year of life or an affected first-degree relative 
are important diagnostic features.(Teo, Klaassen et al. 2008) A wide range of physical 
anomalies (e.g. craniofacial, skeletal, cardiovascular, gastrointestinal, renal, neurological and 
dermatological) are associated with IBMFSs and may help to establish a diagnosis. 
However, substantial phenotypic overlap exists among the disorders, which frequently 
limits the ability to establish a diagnosis based solely on clinical manifestations. Further, 
some of the disorders are not associated with physical anomalies, or the malformations 
develop later in life; for example, nail dystrophy in dyskeratosis congenita and metaphyseal 
dysplasia in Shwachman-Diamond syndrome. Therefore, genetic testing is critical for 
establishing a diagnosis and provides family counseling and management.  
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Disorder Gene Protein Gene Locus Inheritance Reference 
Fanconi anemia FANCA FANCA 16q24.3 AR (Lo Ten Foe, 
Rooimans et 
al. 1996) 
 FANCB FANCB Xp22.31 XLR (Meetei, 
Levitus et al. 
2004) 
 FANCC FANCC 9q22.3 AR (Strathdee, 
Gavish et al. 
1992) 
 FANCD1/ 
BRCA2 
FANCD1/ 
BRCA2 
13q12.3 AR 
 
(Howlett, 
Taniguchi et 
al. 2002) 
 FANCD2 FANCD2 3p25.3 AR (Timmers, 
Taniguchi et 
al. 2001) 
 FANCE FANCE 6p21.3 AR (de Winter, 
Leveille et 
al. 2000) 
 FANCF FANCF 11p15 AR (de Winter, 
Rooimans et 
al. 2000) 
 FANCG/ 
XRCC9 
FANCG 9p13 AR (de Winter, 
Waisfisz et 
al. 1998) 
 FANCI FANCI 15q25-q26 AR (Levitus, 
Rooimans et 
al. 2004) 
 FANCJ/ 
BRIP1 
FANCJ/ 
BRIP1 
17q22 AR (Levitus, 
Rooimans et 
al. 2004) 
 FANCL/ 
PHF9 
FANCL/ 
PHF9 
2p16.1 AR (Meetei, de 
Winter et al. 
2003) 
 FANCM FANCM 14q21.3 AR (Meetei, 
Medhurst et 
al. 2005) 
 FANCN/ 
PALB2 
FANCN/ 
PALB2 
16p12 AR (Reid, 
Schindler et 
al. 2007) 
 FANCP/ 
SLX4 
FANCP/ SLX4 16p13.3 AR (Stoepker, 
Hain et al.) 
 FANCO/ 
RAD51C 
FANCO/ 
RAD51C 
17q22 AR (Vaz, 
Hanenberg 
et al.) 
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Disorder Gene Protein Gene Locus Inheritance Reference 
 Mono-somy 
21q22.11-
q22.13  
UK UK UK (Byrd, 
Zwerdling et 
al.) 
Shwachman-
Diamond syndrome
SBDS 7q11.2 7q11 AR (Boocock, 
Morrison et 
al. 2003) 
Dyskeratosis 
congenita  
DKC1 Dyskerin Xq28 XLR (Heiss, 
Knight et al. 
1998) 
 TINF2 TIN2 14q12 AD (Savage, Giri 
et al. 2008) 
 TERC TERC 3q21-q28 AD (Vulliamy, 
Marrone et 
al. 2001) 
 TERT Telomerase 5p15.33 AD (Vulliamy, 
Walne et al. 
2005) 
 NOP10 NOP10 15q14-q15 AR (Walne, 
Vulliamy et 
al. 2007) 
 NHP2 NHP2 5q35.3 AR (Vulliamy, 
Beswick et 
al. 2008) 
 TCAB1 TCAB1 17p13 AR (Zhong, 
Savage et al. 
2011) 
Congenital 
amegakaryocytic 
thrombocytopenia 
MPL Thrombo-
poietin 
receptor 
1p34 AR (van den 
Oudenrijn, 
Bruin et al. 
2000) 
Reticular dysgenesis AK2 Adenylate 
kinase 2 
1p34 AR (Lagresle-
Peyrou, Six 
et al. 2009; 
Pannicke, 
Honig et al. 
2009) 
Pearson’s syndrome mDNA Variable Mito-
chondrial 
DNA 
Maternal (Rotig, 
Cormier et 
al. 1990) 
Lig4-associated 
aplastic anemia 
LIG4 DNA Ligase 
IV 
1q22-q34  (O'Driscoll, 
Cerosaletti 
et al. 2001) 
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Disorder Gene Protein Gene Locus Inheritance Reference 
Diamond-Blackfan 
anemia 
RPS19 RPS19 19q13.3 AD (Draptchins
kaia, 
Gustavsson 
et al. 1999) 
 RPL5 RPL5 1p22.1 AD (Gazda, 
Sheen et al. 
2008) 
 RPS26  RPS26  12q AD (Doherty, 
Sheen et al. 
2010) 
 RPL11 RPL11 1p35-p36.1 AD (Gazda, 
Sheen et al. 
2008) 
 RPS24 RPS24 10q22-q23 AD (Gazda, 
Grabowska 
et al. 2006) 
 RPL35a RPL35a 3q29 AD (Farrar, 
Nater et al. 
2008) 
 RPS7 RPS7 15q AD (Doherty, 
Sheen et al. 
2010) 
 RPS17 RPS17 15q AD (Doherty, 
Sheen et al. 
2010) 
 RPS10 RPS10 6p AD (Doherty, 
Sheen et al. 
2010) 
Inherited 
sideroblastic anemia
ALAS2 ALAS Xp11.21 XL (Cotter, 
Baumann et 
al. 1992) 
 ABC7 ATP-binding 
cassette 
transporter 7 
Xq13.1-q13.3 XL (Allikmets, 
Raskind et 
al. 1999) 
 SLC19A2 thiamine 
transporter 2 
1q23.3 AR (Fleming, 
Tartaglini et 
al. 1999) 
 
 
 
PUS1 Pseudo-
uridine 
synthase 1 
2p16.1 AR (Zeharia, 
Fischel-
Ghodsian et 
al. 2005) 
 
 
 
SLC25A38 SLC25A38 3p22.1 AR (Guernsey, 
Jiang et al. 
2009) 
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Disorder Gene Protein Gene Locus Inheritance Reference 
Congenital 
dyserythropoietic 
anemia type I 
CDAN1 Codanin-1 15q15 AR (Dgany, 
Avidan et al. 
2002) 
Congenital 
dyserythropoietic 
anemia type II 
SEC23B SEC23B 20p11.2 AR (Bianchi, 
Fermo et al. 
2009; 
Schwarz, 
Iolascon et 
al. 2009) 
Congenital 
dyserythropoietic 
anemia type III 
UK UK UN AR  
Congenital 
dyserythropoietic 
anemia - 
unclassified 
KLF1 KLF1 19p13.12-
p13.13 
AR (Arnaud, 
Saison et al.) 
Kostmann/Severe 
congenital  
neutropenia 
ELA2 Neutrophil 
Elastase 
19p13.3 AD (Dale, 
Person et al. 
2000) 
 HAX1 HAX1 1q21.3 AR (Klein, 
Grudzien et 
al. 2007) 
 GLI1 GFI1 1p22 AD (Person, Li 
et al. 2003) 
 WASP WASP Xp11.23-
p11.22 
XLR (Devriendt, 
Kim et al. 
2001) 
Dursun syndrome G6PC3 Glucose-6-
phosphatase 
catalytic unit 3
17q21  (Banka, 
Newman et 
al. ; Boztug, 
Appaswamy 
et al. 2009) 
Cyclic neutropenia ELA2 Neutrophil 
Elastase 
19p13.3 AD (Horowitz, 
Benson et al. 
1999) 
WHIM syndrome CXCR4 CXCR4 2q21 AD (Hernandez, 
Gorlin et al. 
2003) 
Glycogen storage 
diseases Ib  
G6PT G6PT 11q23 AR (Annabi, 
Hiraiwa et 
al. 1998) 
Barth syndrome TAZ Taffazin Xq28 XL (Bione, 
D'Adamo et 
al. 1996) 
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Disorder Gene Protein Gene Locus Inheritance Reference 
Poikiloderma with 
neutropenia 
C16orf57 Not-
determined 
16q13 AR (Volpi, 
Roversi et 
al.) 
Thrombocytopenia 
absent radii 
UK UK UK AR  
Epstein/Fechtner/ 
Sebastian/May-
Hegglin/ Alport 
syndrome 
MYH9 nonmuscle 
myosin heavy 
chain IIA 
22q11-q13 AD (Seri, Pecci 
et al. 2003) 
Mediterranean 
platelet disorder 
GPIBA GPIb 17pter-p12 AD (Savoia, 
Balduini et 
al. 2001) 
Familial autosomal 
dominant non-
syndromic 
thrombocytopenia 
MASTL 
 
microtubule-
associated 
serine/threoni
ne-like kinase 
10p11-12 AD (Gandhi, 
Cummings 
et al. 2003) 
 ACBD5 ACBD5 10p12.1 AD (Punzo, 
Mientjes et 
al. 2010) 
 ANKRD26 ANKRD26 10q22.1 AD (Pippucci, 
Savoia et al.) 
Thrombocytopenia 
with 
dyserythropoiesis 
GATA1 GATA1 Xp11.23 XL (Nichols, 
Crispino et 
al. 2000) 
Thrombocytopenia 
with associated 
myeloid 
malignancies 
CBFA2 CBFA2 21q22.1-22.2 AD (Song, 
Sullivan et 
al. 1999) 
X-linked 
thrombocytopenia 
WASP WASP Xp11.23 XL (Devriendt, 
Kim et al. 
2001) 
Thrombocytopenia 
with radio-ulnar 
synostosis 
HOXA11 HOXA11 7p15-p14.2 AD (Thompson 
and Nguyen 
2000) 
Table 1. The inherited bone marrow failure syndromes 
2. The inherited bone marrow failure syndromes and genes 
Mutations in IBMFS genes result in high-penetrance alleles; namely alleles that cause 
Mendelian (monogenic) diseases transmitted in a autosomal dominant, autosomal recessive 
autosomal or X-linked recessive patterns.(Balmain, Gray et al. 2003) The IBMFS genes are 
crucial for fundamental cellular processes such as DNA repair,(Cohn and D'Andrea 2008) 
telomere maintenance,(Vulliamy and Dokal 2008) ribosome biogenesis(Choesmel, 
Bacqueville et al. 2007; Ganapathi, Austin et al. 2007; Menne, Goyenechea et al. 2007) 
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microtubule stabilization,(Austin, Gupta et al. 2008) chemotaxis,(Wessels, Srikantha et al. 
2006) signaling from hematopoietic growth factor,(Ihara, Ishii et al. 1999) signal transduction 
related to hematopoietic cell differentiation,(Song, Sullivan et al. 1999; Nichols, Crispino et 
al. 2000) granulocytic enzymes,(Dale, Person et al. 2000) and cell survival.(Cumming, 
Lightfoot et al. 2001; Miyake, Flygare et al. 2005; Klein, Grudzien et al. 2007; Rujkijyanont, 
Watanabe et al. 2008; Watanabe, Ambekar et al. 2009) Although rare, the study of IBMFSs 
genes made critical contributions to the understanding of not only the pathogenesis of the 
individual disorders, but also to common health problems such as cancer(Friedenson 2007; 
Londono-Vallejo 2008) and aging.(Aubert and Lansdorp 2008) 
2.1 Fanconi anemia 
2.1.1 Clinical features of Fanconi anemia 
Fanconi anemia (FA) is an IBMFS with increased chromosome breakage. It has the highest 
child birth incidence among the IBMFSs.(Tsangaris, Klaassen et al. 2011) It was first 
described by Professor Fanconi in 1927. (Fanconi 1927) It is a multisystem disorder which 
commonly affects the bone marrow and the development of other organs.(Auerbach, 
Rogatko et al. 1989) Hematologically the patients suffer from aplastic anemia, which is 
characterized by various degrees of single or multilineage cytopenia, red blood cell 
macrocytosis, high fetal hemoglobin levels and reduced bone marrow cellularity. Common 
malformations include cafe-au-lait spots, hypopigmented skin patches, hypoplasia/absence 
of the thumbs, dysplastic/absence kidneys, characteristic delicate faces, microcephaly, 
developmental delay and various heart defects. Also, the patients have a high 
predisposition for myelodysplastic syndrome (MDS), leukemia (particularly acute myeloid 
leukemia, AML) and solid cancer. The cumulative incidence of developing bone marrow 
failure, MDS/AML and solid neoplasms were estimated at 90%, 33%, and 28% by 40 years 
of age.(Kutler, Singh et al. 2003) At presentation patients may have an either classic 
phenotype comprised of both physical anomalies and abnormal hematology, or typical 
physical anomalies but normal hematology, or normal physical features but abnormal 
hematology. The disease occurs in all racial and ethnic groups. The treatment for the bone 
marrow failure includes androgens or hematopoietic stem cell transplantation (HSCT). The 
later is the only curative therapy for the bone marrow failure. Surgical interventions may be 
required for some organ malformations or cancer. 
2.1.2 Fanconi anemia genes 
FA is a genetically heterogeneous disease with 15 genes currently identified (Table 1). Most 
genetic groups are inherited in an autosomal recessive manner with an estimated overall FA 
heterozygote frequency of about 1 in 200. This was confirmed with the identification of the 
FA genes. However, a XL-recessive inheritance characterizes the rare FA group B. The most 
commonly mutated FA genes are FANCA, FANCC and FANCG. Based on the ability to 
correct the chromosome fragility phenotype by forming hybrid cells with another genetic 
group cells(Yoshida 1980; Duckworth-Rysiecki, Cornish et al. 1985) or by vector-mediated 
gene transduction,(Antonio Casado, Callen et al. 2007) each genetic group is also called 
complementation group.  
DNA Repair 
A major finding in FA is abnormal chromosome fragility; this is seen in metaphase 
preparations of peripheral blood lymphocytes or cultured skin fibroblasts either 
www.intechopen.com
 
Advances in the Study of Genetic Disorders 364 
spontaneously or after treating the cells with DNA cross linking agents such as mitomycin 
C, di-epoxybutane and cisplatinum (Fig 1). The FA cellular karyotype shows chromatid 
breaks, rearrangements, gaps, endoreduplications, and chromatid exchanges. Spontaneous 
chromosomal breaks are occasionally absent in FA,(Auerbach, Rogatko et al. 1989) but is  
strikingly enhanced if cross linking agents are added to the cell culture.(Auerbach, Rogatko 
et al. 1989) It is postulated that the increased chromosomal fragility is caused by a defects in 
DNA repair. Indeed, some of the FA genes have been previously shown to be tumor 
suppressor genes related to DNA repair.(Mavaddat, Pharoah et al. 2010) FANCD1 is BRCA2, 
which is mutated in the germline of 12% of patients with familial breast cancer and also 
contributes to a risk of ovarian and pancreatic cancer. FANCJ was identified as BRIP1 or 
BACH1, which is mutated in 1-2% of familial breast cancer.  FANCN is PALB2 which is 
mutated 1-2% of familial breast cancer. 
The FA genes might have variety of functions, but all belong to the FA homologous 
recombination DNA repair pathway (Reviewed by de Winter & Joenje(de Winter and Joenje 
2008)) (Fig 2). During S phase, the replication forks are stalled in areas of DNA interstrand 
crosslinks. FANCM associates with FAAP24, which senses the stalled replication forks. 
FANCM then recruits the FA core complex to chromatin at the site of DNA damage.(Huang 
2010) The core FA complex is composed of FANCA,B,C,E,F,G,L,M, which associate with 
each other in a stepwise manner. Activation of the FA core complex via phosphorylation of 
FANCA, FANCE, FANCD2 and FNACI occurs in response to DNA damage in an ATR 
dependent manner. The complex is required for monoubiquination of two downstream FA 
proteins, FANCD2 and FANCI, through the E3 ubiquiten ligase domain of FANCL and by 
the E2 conjugating enzyme UBE2T. There is evidence that FANCI phosphorylation 
promotes FAND2 monoubiquination in an ATR-dependent manner and functions as a 
molecular switch to turn on the FA pathway.(Ishiai, Katao et al. 2008) Once ubiquinated, 
FANCD2 and FANCI bind to chromatin at DNA damage foci. Other DNA repair proteins 
that are recruited to these foci are FANCD1, BRCA1, RAD51, NSB1, BLM and PCNA. The 
recruitment of FANCD2 and FANCI to DNA damage foci likely facilitates DNA repair 
through homologous recombination, nucleotide excision repair and translesion synthesis; 
however, the exact biochemical functions are still unclear. FANCO (RAD51C) protein is 
critical for formation of RAD51 foci in response to DNA damage.(Godthelp, Artwert et al. 
2002; Smeenk, de Groot et al. 2010)  FANCP (SLX4) is a regulator of structure-specific 
endonucleases that repair DNA interstrand crosslinks. (Fekairi, Scaglione et al. 2009) The FA 
protein-related DNA damage foci are thought to be assembled during S phase and mostly 
disassembled once the damage is repaired, before the exit from S phase. 
Mutations in any member of the core FA protein complex reduces FANCD2 ubiquitinylation 
and its recruitment to DNA damage foci.(Garcia-Higuera, Taniguchi et al. 2001) Mutations 
in downstream FANC proteins such as FANCD1 prevent localization of DNA repair 
proteins such as RAD51 in damage-induced nuclear foci,(Godthelp, Artwert et al. 2002; 
Howlett, Taniguchi et al. 2002) but do not affect FAND2 monoubiquination. 
Apoptosis 
The FA proteins might also be directly involved in protecting cells from apoptosis. 
Enhanced apoptosis of hematopoietic stem cells progenitors is probably a key cellular 
mechanism promoting bone marrow failure in FA. Most of apoptosis-related work was 
done on the FANCC subgroup. First, FANCC associates with HSP70, upon exposure to 
either combinations of tumor necrosis factor and interferon-gamma or double-stranded 
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RNA and interferon-gamma. This interaction facilitates HSP70 binding to and inactivation 
of double-stranded RNA-dependent protein kinase, thereby protecting from 
apoptosis.(Pang, Keeble et al. 2001) Mutations in the FANCA, FANCC, and FANCG genes 
markedly increase the amount of RNA-dependent protein kinase, leading to 
hypersensitivity of hematopoietic progenitor cells to growth inhibition by interferon-┛ and 
tumor necrosis factor-┙.(Zhang, Li et al. 2004) Second, it has been shown that FANCC 
interacts with and enhances the function of GSTP1, which detoxifies by-products of redox 
stress and xenobiotics, whereby it might protect cells from inducers of apoptosis.(Cumming, 
Lightfoot et al. 2001) Third, it has also been shown that oxidative stress through excess 
inflammatory cytokines such as tumor necrosis factor-┙ may contribute to the loss of FA 
hematopoietic stem cells/early progenitors. High production of inflammatory cytokines 
including tumor necrosis factor-┙ was observed in FA patients(Dufour, Corcione et al. 2003) 
and in Fancc–/– mice challenged with lipopolysaccharide.(Sejas, Rani et al. 2007) Fancc–/– 
hematopoietic progenitors are hypersensitive inflammatory mediators such as interferon-┛ 
and lipopolysaccharide with a concomitant increase in tumor necrosis factor-┙-dependent 
apoptosis.(Sejas, Rani et al. 2007) Importantly, the inflammatory-related apoptosis in FA 
requires the production of reactive oxygen species. It has been shown that enhanced oxidant 
and tumor necrosis factor- ┙–induced apoptosis in Fancc–/– murine hematopoietic 
progenitors is dependent on apoptosis signal-regulating kinase 1.(Bijangi-Vishehsaraei, 
Saadatzadeh et al. 2005) Abnormal p38 MAPK and JNK activation was shown to partially 
contribute to lipopolysaccaride-induced Fancc–/– hematopoietic suppression. Saadatzadeh et 
al(Saadatzadeh, Bijangi-Vishehsaraei et al. 2009) showed that p38 MAPK and JNK inhibition 
protected c-kit+ bone marrow cells from tumor necrosis factor-┙-induced apoptosis and 
enhanced Fancc–/– hematopoietic colony formation in the presence of tumor necrosis factor-
┙. However, engraftment and in-vivo hematopoietic reconstitution might be inhibited by 
p38MAPK rather than JNK. 
Replication fork progression  
FANCM has been proposed to directly function in DNA replication and repair. It contains 
ATP-dependent translocase activity, which promotes replication fork reversal(Gari, 
Decaillet et al. 2008) and has been proven to control replication fork.(Luke-Glaser, Luke et 
al. 2010)  
Cytokinesis 
FA cells demonstrate G2-phase cell cycle arrest.(Sabatier and Dutrillaux 1988) A small 
number of monoubiquinated FANCD2/FANCI foci localize to DNA fragile sites, persist 
into mitosis(Chan, Palmai-Pallag et al. 2009; Naim and Rosselli 2009) and mark the 
extremities of ultrafine DNA bridges;(Chan, Palmai-Pallag et al. 2009) ssDNA which link the 
centromeres of sister chromatids during mitosis.(Chan, North et al. 2007) The ultrafine DNA 
bridges are naturally coated by BLM and Plk-interacting checkpoint helicase (PICH) 
(Baumann, Korner et al. 2007; Chan, North et al. 2007) The ultrafine DNA bridges which 
contain PICH and BLM also display FANCD2/FANCI foci at their extremities. They are 
generated when replication is incomplete, particularly at fragile loci under replication 
stress, but also in between two replication forks. BLM participates in the resolution of 
these bridges during mitosis and persistent DNA bridges may lead to 
micronucleation.(Chan, Palmai-Pallag et al. 2009) Vinciguerra et al.(Vinciguerra, Godinho 
et al. 2010) demonstrated abnormally high number of ultrafine DNA bridges in cellular 
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models of FA, which was correlated with a higher rate of cytokinesis failure and 
formation of binucleated cells. 
 
.  
Fig. 1. Characteristic chromosome fragility seen in Fanconi anemia (chtb, chromatid break; 
chtg, chromatid gap; r, ring; ace, acentric fragment; tr, tri-radial figure) 
 
 
Fig. 2. The Fanconi anemia gene pathway and its reaction to DNA damage. The genes 
encoding for the proteins in bold are mutated in Fanconi anemia 
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2.1.3 Genotype phenotype correlation 
The abnormal chromosome pattern, number of breaks/cell and variations in proportion of 
abnormal cells have no direct correlation with the severity of the hematological defects or 
clinical course of individual patients. (Gillio, Verlander et al. 1997) However, sensitivity to 
interstrand linking inducing agents may correlate with increased physical malformations. 
(Castella, Pujol et al. 2011)  
A certain degree of correlation exists between genotype and phenotype. FA group A 
patients with homozygous for null mutations tend to have an earlier onset of anemia and a 
higher incidence of leukemia than those with mutations producing an altered protein. 
(Faivre, Guardiola et al. 2000) Also, FA group C patients with IVS4+4A>T or exon 14 
mutations usually, (Gillio, Verlander et al. 1997; Faivre, Guardiola et al. 2000) but not 
always, (Futaki, Yamashita et al. 2000) have more somatic abnormalities and earlier onset of 
hematological abnormalities and poorer survival compared to patients with other FANCC 1 
mutation. FA group G patients have severe cytopenia and a higher incidence of leukemia. 
FA group D1 and N patients may present with solid cancer without apparent bone marrow 
failure or physical anomalies. Common types of cancer in these groups include 
medulloblastoma, Wilm’s tumor and AML. 
2.2 Shwachman-Diamond syndrome 
2.2.1 Clinical features of Shwachman-Diamond syndrome 
SDS is an autosomal recessive multi-system disorder.(Shwachman 1964) It usually presents in 
childhood and commonly includes bone marrow failure, exocrine pancreatic insufficiency and 
bony metaphyseal syaplasia.(Aggett, Cavanagh et al. 1980) The patients have a high risk of 
leukemia, particularly AML.(Donadieu, Leblanc et al. 2005) The clinical diagnosis of SDS relies 
on having an evidence of bone marrow dysfunction and exocrine pancreatic dysfunction.  
Neutropenia is the most common hematological abnormality, occurring in virtually all 
patients, followed by reticulocytopenic anemia and thrombocytopenia. Trilineage 
cytopenias occur in up to 65% of patients. Severe aplastic pancytopenia has occasionally 
been reported.(Aggett, Cavanagh et al. 1980; Tsai, Sahdev et al. 1990; Barrios, Kirkpatrick et 
al. 1991) Various degrees of abnormalities in B and T-cell lymphocytes as well as natural 
killer cells have also been reported in SDS.(Hudson and Aldor 1970; Aggett, Cavanagh et al. 
1980; Dror, Ginzberg et al. 2001)  Bone marrow biopsy usually shows a hypoplastic 
specimen.(Aggett, Cavanagh et al. 1980; Dror and Freedman 1999) The only curative therapy 
for the hematological complications in SDS is HSCT.(Donadieu, Michel et al. 2005)  
2.2.2 The Shwachman-Diamond syndrome gene 
SBDS is the only gene currently known to be associated with SDS. Mutations in SBDS can be 
identified in 90% of the patients.(Boocock, Morrison et al. 2003) SBDS was originally 
identified by Lai and colleagues(Lai, Chou et al. 2000) in 2000. The protein is 250 amino 
acids-long, and is highly conserved in evolution. Three structural/functional domains were 
predicted for the human(de Oliveira, Sforca et al.) and archael(Shammas, Menne et al. 2005) 
orthologues. The SBDS N-terminal domain was postulated to play a role in protein-protein 
interaction, the central domain is predicted to bind DNA,(Luscombe, Austin et al. 2000) and 
the C-terminus to bind RNA.(Birney, Kumar et al. 1993)  
Data from the Canadian registry showed that SBDS is the most commonly mutated gene 
among the IBMFSs. This is probably because SDS is a common IBMFS and genetically 
homogenous.(Tsangaris, Klaassen et al. 2011) SBDS was mutated in 85%-90% of the SDS 
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patients.(Boocock, Morrison et al. 2003) The other 10-15% of the patients were diagnosed 
based on clinical characteristics, and are likely to have mutations in an additional, yet 
unknown, SDS gene(s). 
Ninety six percent of the SBDS mutations are in exon 2.(Boocock, Morrison et al. 2003) The 
type of mutations include nonsense, splice site mutation, frameshift, missense and complex 
rearrangements comprising of deletion/insertion. The two common mutations are 183-
184TA>CT (nonsense) and 258+2T>C (intronic with predicted alternative splicing & 
frameshift reading). The mutations are mostly in the N-terminal domain of the protein and 
cause markedly reduced protein levels.(Woloszynek, Rothbaum et al. 2004) 
SBDS mRNA is ubiquitously expressed.(Boocock, Morrison et al. 2003)  The protein is 
essential as no patients with homozygous null mutations have been reported, and residual 
protein levels can usually be detected in SDS patients.(Woloszynek, Rothbaum et al. 2004; 
Austin, Leary et al. 2005)  Further, a complete loss of the protein in mice causes 
developmental arrest prior to embryonic day 6.5 and early lethality.(Zhang, Shi et al. 2006) 
SBDS seems to be multifunctional and play a role in several cellular pathways. 
Ribosomal biogenesis 
SBDS was found by one group to concentrate in the nucleolus during G1 and G2,(Austin, 
Leary et al. 2005) and is associated with rRNA.(Ganapathi, Austin et al. 2007) Synthetic 
genetic arrays of YHR087W, a yeast homolog of the N-terminal domain of SBDS, suggested 
interactions with several genes involved in RNA and rRNA processing.(Savchenko, Krogan 
et al. 2005) The loss of the protein in yeast results in a defect in maturation of the 60S 
ribosomal subunit due to defect in release and recycling of the nucleolar shuttling factor 
TIF6 from pre-60S ribosomes (Fig 3).(Menne, Goyenechea et al. 2007) 
Apoptosis 
Bone marrow cells from patients with SDS are characterized by decreased frequency of 
CD34+ progenitors,(Dror and Freedman 1999) and a reduced ability to generate 
hematopoietic colonies of all lineages in vitro.(Dror and Freedman 1999) Marrow cells(Dror 
and Freedman 2001) as well as SBDS-knockdown HeLa cells(Rujkijyanont, Watanabe et al. 
2008) are characterized by accelerated apoptosis.(Dror and Freedman 2001) The accelerated 
apoptosis in marrow cells and SBDS-knockdown cells seems to be through the FAS pathway 
and not through the BAX/BCL-2/BCL-XL pathway.(Dror and Freedman 2001; Rujkijyanont, 
Watanabe et al. 2008) Depletion of SBDS results in accumulation of FAS at the plasma 
membrane level and specific overexpression of FAS transcript 1; the main FAS transcript 
which contains both the transmembrane domain and the death domain. 
Chemotaxis 
SDS patients have a defect in leukocyte chemotaxis.(Dror, Ginzberg et al. 2001; Stepanovic, 
Wessels et al. 2004) Consistent with this observation, the SBDS homologue in ameba was 
found to localize to the pseudopods during chemotaxis.(Wessels, Srikantha et al. 2006) 
These observations suggest that the SBDS-deficiency in SDS causes the chemotaxis defects in 
patients.  
Mitotic spindle formation 
SBDS has been shown to localize to the mitotic spindle, binds microtubles and stabilize 
them.(Austin, Gupta et al. 2008) Its deficiency results in centrosomal amplification and 
multipolar spindles.  
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Bone marrow stromal function 
SDS bone marrows are also characterized by a defect in the ability of the stroma to support 
normal hematopoiesis in cross over experiments of normal CD34+ cells over SDS 
stroma.(Dror and Freedman 1999) 
 
 
Fig. 3. Ribosome biogenesis and the steps where the inherited bone marrow failure 
syndrome proteins that are known or hypothesized to function 
2.2.3 Genotype phenotype correlation 
The study of genotype-phenotype correlation in SDS is difficult since most patients have at 
least one of the two common mutations. Nevertheless, with regard to the common 
mutations, patients with severe phenotype including major skeletal abnormalities (Makitie, 
Ellis et al. 2004) or AML(Majeed, Jadko et al. 2005) have been found to have common 
mutations. 
Based on relatively small numbers is was suggested that SDS patients without mutations in 
the SBDS coding region or flanking intronic regions had more severe hematological disease 
(lower hemoglobin levels and higher incidence of severe bone marrow failure) but milder 
pancreatic disease compared to patients with biallelic SBDS mutations.(Hashmi, Allen et al. 
2010)  
2.3 Dyskeratosis Congenita 
2.3.1 Clinical features of Dyskeratosis Congenita 
Dyskeratosis congenital (DC) is characterized by mucocutaneous abnormalities,(Zinnsser 
1906; Cole, Rauschkolb et al. 1920) bone marrow failure,(Dokal 2000) cancer 
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predisposition(Dokal 2000) and extreme telomere shortening.(Vulliamy, Knight et al. 2001) 
With the recent advances in understanding the molecular basis of the disease, patients with 
hematological abnormalities without dermatological anomalies have been identified, which 
changed dramatically the historical definition of the disease.(Vulliamy, Marrone et al. 2002) 
The original diagnostic triad included oral leukoplakia, nail dystrophy and skin 
hyperpigmentation. Patients may have many other manifestations including 
immunodeficiency, dacryostenosis, urethral meatal stenosis, pulmonary fibrosis, hepatic 
fibrosis and gastrointestingal bleeding due to vascular anomalies. The treatment for the 
bone marrow failure includes androgens or HSCT. Surgical interventions may be required 
for some organ malformations or solid cancer. 
2.3.2 Dyskeratosis Congenita genes 
Multiple genes have been associated with DC.(Heiss, Knight et al. 1998; Vulliamy, Marrone 
et al. 2001; Vulliamy, Walne et al. 2005; Marrone, Walne et al. 2007; Walne, Vulliamy et al. 
2007; Savage, Giri et al. 2008; Vulliamy, Beswick et al. 2008) All are components of the 
telomerase complex or shelterin (Fig 4). The X-linked recessive disease is a common form of 
DC. It was originally estimated as more than 50%, but with the identification of more DC 
genes and more patients with autosomal dominant inheritance, the true incidence seems 
lower at approximately 30%. The X-linked disease is caused by mutations in DKC1 on 
chromosome Xq28.(Heiss, Knight et al. 1998) DKC1, encodes for the protein dyskerin. 
Dyskerin associates with the H/ACA class of RNA. Dyskerin binds to the 3' H/ACA small 
nucleolar RNA-like domain of the TERC component of telomerase. This stimulates 
telomerase to synthesize telomeric repeats during DNA replication. Dyskerin is also 
involved in maturation of nascent rRNA. It binds to small nucleolar RNA through their 3' 
H/ACA domain and catalyzes the isomerization of uridine to pseudouridine through its 
peudouridine synthase homology domain. This might be the mechanism for impaired 
translation from internal ribosome entry sites seen in mice and human DC cells. 
There are several genes which are mutated in families with autosomal dominant inheritance.  
TINF2 is probably the most commonly mutated gene in this group and accounts for 
approximately 11-25% of the DC families.(Walne, Vulliamy et al. 2008) TINF2 protein is part 
of the shelterin protein complex, which binds to telomeres and prevent their recognition as 
DNA breaks by DNA repair proteins. In the complex, TIN2 binds to TRF1, TRF2, POT1, 
TPP1 and RAP1. 
Heterozygous mutations in TERT results in autosomal dominant disease. TERT encodes for 
the enzyme component of telomerase. Telomerase is a ribonucleoprotein polymerase that 
maintains telomere ends by synthesis and addition of the telomere repeat TTAGGG at the 
3’-hydroxy DNA terminus using the TERC RNA as a template. 
Heterozygous mutations in the TERC gene are another cause an autosomal dominant form 
of DC.(Vulliamy, Marrone et al. 2001) TERC, encodes for the RNA component of telomerase 
and has a 3' H/ACA small nucleolar RNA -like domain. 
The autosomal recessive forms of DC are caused by biallelic mutations in NOP10, NHP2, 
TERT or TCAB1. In the telomerase complex, the H/ACA domain of nascent human 
telomerase RNA forms a pre-ribonucleoprotein with NAF1, dyskerin, NOP10, and NHP2. 
Initially the core trimer dyskerin-NOP10-NHP2 is forms to enable incorporation of 
NAF1,(Trahan and Dragon 2009; Trahan, Martel et al. 2010) and efficient reverse 
transcription of telomere repeats. NOP10 and NHP2 also play an essential role in the 
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assembly and activity of the H/ACA class of small nucleolar ribonucleoproteins, which 
catalyze the isomerization of uridine to pseudouridine in rRNAs.  
TCAB1 facilitates trafficking of telomerase to Cajal bodies. Mutations in this gene lead to 
misdirection of telomerase RNA to nucleoli and prevent elongation of telomeres by 
telomerase.(Zhong, Savage et al. 2011) 
DC cells are characterized by very short telomeres. In several acquired and inherited 
marrow failure syndromes, telomere length is reduced. However, since the telomerase 
function is profoundly impaired in DC, the telomeres in this disease are very short (<1% of 
the median range for normal). Shortening of telomeres results in senescence, apoptosis 
(“cellular crisis”) or chromosome instability. However, some cells may survive the crisis by 
harboring compensatory genetic mutations which confer proliferative advantage and 
neoplastic potential. 
DC is a chromosome ‘instability’ disorder of a different type than Fanconi anemia.(Dokal 
2000) Clastogenic stress studies of DC cells are normal.(Pai, Yan et al. 1989; Dokal 2000) 
However, probably due to the short telomeres, in some patients metaphases in peripheral 
blood cells, marrow cells and fibroblasts in culture showed numerous spontaneous 
unbalanced chromosome rearrangements such as dicentric, tricentric and translocations. 
Clonogenic assays of marrow cells showed a marked reduction or absence of CFU-GEMM, 
BFU-E, CFU-E and CFU-GM progenitors.(Saunders and Freedman 1978; Marsh, Will et al. 
1992)  
 
 
Fig. 4. Telomeres and the dyskeratosis congenita proteins 
2.3.3 Genotype phenotype correlation 
DC with mutations in the DKC1, TINF2 can result in a severe form of DC called Hoyeraal 
Hreidarsson syndrome. It is characterized by hematological and dermatological 
manifestations of dyskeratosis congenita in addition to cerebellar hypoplasia. Immune 
deficiency is common when the syndrome is caused by DKC1 mutations. Revez syndrome is 
a combination of classical manifestations of DC and exudative retinopathy. It is caused by 
mutations in TINF2.  Biallelic mutations in TERT are also associated with a severe form of 
DC. However, heterozygosity for mutations in TERT is associated with milder 
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phenotype,(Song, Sullivan et al. 1999) late presentation, severe aplastic anemia without 
physical malformations, pulmonary fibrosis and hepatic fibrosis. Heterozygosity for 
mutations in TERC is associated milder phenotype, late presentation and severe aplastic 
anemia without physical malformations. (Song, Sullivan et al. 1999) 
2.4 Diamond Blackfan anemia 
2.4.1 Clinical features of Diamond Blackfan anemia 
Diamond–Blackfan anemia (DBA) is an inherited form of pure red cell aplasia. (Diamond 
and Blackfan 1938) It is the second most common IBMFSs with incidence of approximately 
10 cases/million live births. (Tsangaris, Klaassen et al. (Under Revision)) DBA was first 
reported in 1936 and later described by Diamond and Blackfan in 1938. It is characterized by 
varying degrees of red cell aplasia. (Lipton, Atsidaftos et al. 2006; Vlachos, Ball et al. 2008; 
Lipton and Ellis 2009) Patients may present at birth or become symptomatic after birth with 
pallor, weakness and cardiac failure. Physical anomalies including short stature, craniofacial 
dysmorphism, thumb anomalies, among others. (Lipton, Atsidaftos et al. 2006; Vlachos, Ball 
et al. 2008; Lipton and Ellis 2009) Additionally, patients with DBA carry a high risk of 
developing malignancies including MDS/AML, osteosarcoma and Hodgkin lymphoma. 
(Lipton, Atsidaftos et al. 2006; Vlachos, Ball et al. 2008) 
Many patients can be diagnosed clinically based on having anemia, low reticulocytes, 
reduced marrow erythroid progenitors, characteristic physical malformations and high 
adenosine deaminase levels. (Vlachos, Ball et al. 2008) However, mutations in several genes 
encoding ribosome proteins have been found mutated in DBA,(Draptchinskaia, Gustavsson 
et al. 1999; Gazda, Grabowska et al. 2006; Farrar, Nater et al. 2008; Gazda, Sheen et al. 2008; 
Cmejla, Cmejlova et al. 2009) and can help to establish a diagnosis in many cases when the 
diagnosis is unclear. (Lipton and Ellis 2009) Standard treatment options include chronic 
administration of low-dose prednisone (after induction with 2mg/kg/day), chronic red 
blood cell transfusions and HSCT from a related donor. 
2.4.2 Diamond Blackfan anemia genes 
About 80% of DBA cases are sporadic.(Halperin and Freedman 1989) The discovery of 11 
DBA genes demonstrated heterozygosity for mutations in the respective genes; consistent 
with autosomal dominant inheritance in all currently known genetic groups. All known 
DBA proteins are structural components of either the small or large ribosomal 
subunits.(Doherty, Sheen et al. ; Draptchinskaia, Gustavsson et al. 1999; Farrar, Nater et 
al. 2008; Gazda, Sheen et al. 2008) The most common mutated DBA gene is RPS19. It is 
mutated in about 25% of the patients.(Gazda, Sheen et al. 2008; Cmejla, Cmejlova et al. 
2009) RPS19 encodes for the ribosomal protein S19, which is associated with the ribosomal 
subunit 40S.(Da Costa, Tchernia et al. 2003) Deficiency in RPS19 causes defective cleavage 
of the pre-rRNA at the ITS1 sequence and abnormal maturation of the 40S subunit (Fig 
3).(Flygare, Aspesi et al. 2007) Its deficiency leads to apoptosis of erythroid 
progenitors,(Miyake, Utsugisawa et al. 2008) possible in a p53 dependent manner. 
(McGowan, Li et al. 2008)  
Other ribosomal protein genes that are mutated in DBA are RPL5 (12-21%),(Doherty, Sheen 
et al. ; Gazda, Sheen et al. 2008; Cmejla, Cmejlova et al. 2009) RPL11 (7-9%),(Gazda, Sheen et 
al. 2008; Cmejla, Cmejlova et al. 2009) RPS24 (2%),(Gazda, Grabowska et al. 2006; Gazda, 
Sheen et al. 2008; Cmejla, Cmejlova et al. 2009) RPL35a(Farrar, Nater et al. 2008) and other 
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more rarely mutated (Table 1). Despite the identification of multiple genes, only about 50% 
of the patients with DBA can now be genotyped,(Gazda, Sheen et al. 2008; Cmejla, Cmejlova 
et al. 2009) and new DBA genes are still to be discovered. 
DBA marrows are characterized by complete or nearly complete absence of erythroid 
precursors in 90% of the patients. The defect in DBA is intrinsic to the hematopoietic stem 
cells and selectively limits their ability to differentiate into and expand the erythroid 
compartment. DBA erythroid progenitors demonstrate subnormal colony growth in 
response to erythropoietin.(Tsai, Arkin et al. 1989) Clonogenic assays of marrow cells or 
CD34+ cells typically show absent BFU-E and CFU-E progenitors. Some patients show 
normal or even increased numbers of both progenitors or a block at the BFU-E stage. The 
colony growth can be improved in vitro by the addition of combinations of glucocorticoids 
and erythropoietin. (Chan, Saunders et al. 1982) DBA CD34+ cells had impaired ability also 
to undergo granulocytic-monocytic differentiation in addition to their erythroid 
differentiation defect.(Santucci, Bagnara et al. 1999) These results underscore a stem cell 
defect in DBA rather than an isolated erythroid defect. This is in keeping with the clinical 
observation that in addition to anemia patients can have neutropenia and 
thrombocytopenia.(Schofield and Evans 1991; Giri, Kang et al. 2000) The exact role of the RP 
genes such as RPS19 in erythropoiesis is unclear. RPS19 expression is highest at the earlier 
stages of erythropoiesis and decreases with differentiation.(Da Costa, Narla et al. 2003) Gene 
transfer of the wild type RPS19 into CD34+ cells from DBA patients with RPS19 mutations 
improves erythroid colony growth,(Hamaguchi, Ooka et al. 2002) proving the causative role 
of mutations in the gene in the pathogenesis of DBA. Studies of CD34+ cells from DBA 
patients and CD34+ cells in which RPS19 expression was reduced by approximately 50% 
showed that RPS19 promotes cell proliferation as well as differentiation into CFU-E 
progenitors.(Miyake, Flygare et al. 2005) Intermediate levels of RPS19 to approximately 
haploinsufficiency levels does not affect myeloid progenitors(Bagnara, Zauli et al. 1991; 
Olivieri, Grunberger et al. 1991) or megakaryocytic progenitors.(Bagnara, Zauli et al. 1991) It 
is likely that the genetic defects in the DBA gene/s accelerates apoptosis of erythroid 
progenitor cells(Perdahl, Naprstek et al. 1994; Flygare, Kiefer et al. 2005)  
2.4.3 Genotype phenotype correlation 
Patients with mutations in RPL5 and RPL11 are more likely to have multiple physical 
malformations.(Gazda, Sheen et al. 2008; Boria, Garelli et al. 2010) For example, thumb 
anomalies are seen in 56% and 39% of the patients with RPL5 and RPL11 mutations, 
respectively compared to 7% in patients who have RPS19 gene mutations. Interestingly, cleft 
lip and/or palate were reported in 42% of the patients with RPL5 mutations compared to 6% 
and 0% among the patients with RPL11 and RPS19 gene mutations. 
2.5 Kostmann/Severe congenital neutropenia 
2.5.1 Clinical features of Kostmann/severe congenital neutropenia 
Kostmann neutropenia and severe congenital neutropenia (K/SCN) comprise a 
heterogeneous group of disorders. Herein, we will refer to K/SCN as disorders that are 
characterized by severe subtype of inherited neutropenia with typical onset at early 
childhood, profound neutropenia (absolute neutrophil count < 200/ml), recurrent life-
threatening infections and a maturation arrest of myeloid precursors at the promyelocyte-
myelocyte stage of differentiation. The mainstay of treatment is life-long daily injection with 
granulocyte-colony stimulating factor (G-CSF). 
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2.5.2 Kostmann/Severe congenital neutropenia genes 
The original families described by Dr. Kostmann showed an inheritance typical of an 
autosomal recessive disorder.(Kostmann 1956) However, patients with severe congenital 
neutropenia with an autosomal dominant inheritance mode usually have exactly the same 
clinical phenotype. 
The most common K/SCN gene is ELA2, which is associated with an autosomal dominant 
K/SCN.(Dale, Person et al. 2000) The prevalence of ELA2 mutations seems to be higher in 
North America than in Europe, and was reported in about 40-80% of the K/SCN patients. 
(Horwitz, Benson et al. 1999; Xia, Bolyard et al. 2009) Although some healthy family 
members have been reported to have the same ELA2 Genotype as their affected family 
members, (Germeshausen, Schulze et al. 2001) and although there is a lack of neutropenia in 
homozygous and heterozygous knock-out mice,(Belaaouaj, McCarthy et al. 1998) it is now 
widely accepted that ELA2 mutations are causative. (Ancliff, Gale et al. 2002; Horwitz, 
Benson et al. 2003) 
ELA2 encodes for neutrophil elastase, a glycoprotein synthesized in the promyelocyte/ 
myelocyte stages,(Fouret, du Bois et al. 1989) is packed in the azurophilic cytoplasmic 
granules, and released in response to infection and inflammation.(Cowland and Borregaard 
1999) Computerized modeling of neutrophil elastase showed that ELA2 mutations in 
K/SCN tend to cluster on the opposite face of the active site of the enzyme in contrast to 
cyclic neutropenia, where the mutations tend to cluster near the active site. (Dale, Person et 
al. 2000) 
Neutrophil elastase normally localizes diffusely throughout the cytoplasm.(Benson, Li et al. 
2003; Massullo, Druhan et al. 2005) The mutations in the protein are predicted to disrupt its 
AP3 protein recognition sequence, resulting in excessive membrane accumulation of 
elastase,(Benson, Li et al. 2003; Massullo, Druhan et al. 2005) leading to premature apoptosis 
of differentiating (myeloblasts and promyelocytes) but not proliferating myeloid progenitor 
cells.(Aprikyan, Kutyavin et al. 2003; Massullo, Druhan et al. 2005) Also, there is evidence 
that unfolded protein response occurs in primary granulocytic precursors from K/SCN 
patients and that expression of mutant neutrophil elastase induces unfolded protein 
response and apoptosis.(Grenda, Murakami et al. 2007)  
HAX1 was reported to be mutated in 40% of patients with K/SCN in a European 
study,(Klein, Grudzien et al. 2007) but in none of the patients in the American studies, (Xia, 
Bolyard et al. 2009) and in none of the patients on the Canadian Inherited Marrow Failure 
Study.(Tsangaris, Klaassen et al. 2011) HAX1 localizes to the mitochondria. It contains two 
domains reminiscent of a BH1 and BH2 of the BCL-2 family. It promotes normal potential of 
the inner mitochondrial membrane and protects myeloid cells from apoptosis. 
Mutations in the gene encoding the transcriptional repressor GFI1 were also identified in 
severe congenital neutropenia.(Person, Li et al. 2003) The mutated protein appears to cause 
overexpression of ELA2, and higher neutrophil elastase levels in all subcellular 
compartments. GFI1–deficient mice also exhibit severe neutropenia. (Karsunky, Zeng et al. 
2002) 
Activating WASP gene mutations are another cause of severe congenital neutropenia. 
(Devriendt, Kim et al. 2001) The mutant protein is constitutively activated due to disruption 
of the autoinhibitory domain, leading to increased actin polymerization, disruption of 
mitosis, genomic instability and apoptosis of neutrophils. (Devriendt, Kim et al. 2001)  
Germline G-CSFR mutations are a rare cause of K/SCN. One patient in our registry had 
digenic germ line mutations in ELA2 and the extracellular domain of the G-CSFR. Others 
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have also described digenic mutations in patients with K/SCN. (Germeshausen, Zeidler et 
al. 2010)  
Some patients with K/SCN acquire mutations in the intracytoplasmic domain of the G-CSF 
receptor. The mutations are restricted to the myeloid lineage and a proliferation but not 
differentiation signal. Alterations are associated with the development of MDS/AML, and 
are not the cause of the neutropenia. (Dong, Brynes et al. 1995)   
Severe other types of inherited neutropenia with more distinct phenotype are discussed in 
Section 2.7 “Other inherited bone marrow failure syndromes with predominantly 
neutroepnia” 
2.5.3 Genotype phenotype correlation 
ELA2 mutations are associated with severe and early onset neutropenia with differentiation 
arrest at the stage of promyelocyte-meylocyte. Typically the patients do not have physical 
malformations. The patients have a high risk of MDS/AML, but no known risk of solid 
tumors. 
Patients with mutations in HAX1 typically have severe and early onset neutropenia with 
differentiation arrest at the stage of promyelocyte-meylocyte. They also have a high risk of 
MDS/AML, but no know risk of solid tumors. About 30% of the patients have neurological 
abnormalities such as seizures, learning disabilities and developmental delay. This is 
usually due to nonsense mutations that affect both HAX1 transcripts (e.g. 
p.Gln155ProfsX14). 
Mutations in WAS are associated with moderate to severe neutropenia, reduced phagocyte 
activity; monocytopenia, lymphopenia, reduced NK cells, reduced lymphocyte proliferation 
and recurrent infections (Usually not as frequent as in the classical K/SCN). 
MDS/monosomy 7 has also been reported. 
GFI mutations are associated with severe to moderate neutropenia, monocytosis, reduced B 
and T cells with normal lymphocytic function. There is no clear data about the bone marrow 
findings in this type of neutropenia and the risks of MDS/AML is unknown. 
2.6 Congenital amegakaryocytic thrombocytopenia 
2.6.1 Clinical feature of congenital amegakaryocytic thrombocytopenia 
Congenital amegakaryocytic thrombocytopenia (CAMT) is an IBMFS, which typically 
presents in infancy with predominantly thrombocytopenia due to reduced or absent 
marrow megakaryocytes. It commonly progresses to pancytopenia and severe bone marrow 
failure. In untreated cases, MDS with monosomy 7 and AML can develop at a later stage. 
(Lau, Ha et al. 1999) Non-hematological manifestations occur in about one fifth of the 
patients and include cardiac defects, growth abnormalities, psychomotor retardation (King, 
Germeshausen et al. 2005) and brain structural malformations (Dror, Unpublished Data). 
The only curative treatment is HSCT and is indicated in patients who persistently manifest 
severe cytopenia. 
2.6.2 Congenital amegakaryocytic thrombocytopenia genes 
Biallelic mutations in the MPL (thrombopoietic receptor) gene are the cause for the disorder 
in 94% of the patients with CAMT,26 particularly,(Ballmaier, Germeshausen et al. 2001) but 
not exclusively,(King, Germeshausen et al. 2005) (Dror, Unpublished Data) in those without 
physical anomalies. MPL mutations cause inactivation of the thrombopoietin receptor. The 
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compensatory elevated levels of thrombopoietin(van den Oudenrijn, Bruin et al. 2000; Van 
Den Oudenrijn, Bruin et al. 2002) do not result in transmitting its signaling.(Muraoka, Ishii 
et al. 1997; Ballmaier, Germeshausen et al. 2003) Thrombopoietin plays a critical role in the 
proliferation, survival and differentiation of early and late megakaryocytes. This clearly 
explains the thrombocytopenia. However, MPL is highly expressed in hematopoietic stem 
cells and promotes their quiescence and survival;(Arai, Yoshihara et al. 2009) thus, 
insufficiency may account to depletion of hematopoietic stem cells and pancytopenia. The 
number of CFU-Meg progenitors might be normal initially, but declines as the disease 
progresses (Freedman and Estrov 1990; Guinan, Lee et al. 1993)  
2.6.3 Genotype phenotype correlation 
Data about genotype-phenotype correlation is scarce. Nonesense or frameshift mutations 
that entirely abrogate the thrombopoietin receptor signaling are associated with early 
development of pancytopenia and more severe bone marrow failure. Missense mutations 
which only partially reduce receptor signaling are associated with relatively milder initial 
phenotype and slow progression into pancytopenia.(King, Germeshausen et al. 2005; 
Ballmaier and Germeshausen 2009) However, the overall outcome might not be 
different.(Ballmaier and Germeshausen 2009)   
2.7 Other inherited bone marrow failure syndromes with predominantly neutropenia 
Cyclic neutropenia is an autosomal dominant disorder characterized by a regular, repetitive 
decrease in peripheral blood neutrophils for 3-4 days every 19-23 days.(Page and Good 
1957) Between nadirs the patients have normal or nearly normal neutrophil counts. Patients 
usually present in infancy or childhood, and have a less severe infectious course compared 
to Kostmann/severe congenital neutropenia. However, life threatening infections have been 
reported.(Jonsson and Buchanan 1991; Dale, Bolyard et al. 2002) Daily treatment with G-CSF 
typically improves symptoms in most patients. Cyclic neutropenia is caused by 
heterozygous mutations in the ELA2 gene usually at the active site of neutrophil 
elastase,(Horowitz, Benson et al. 1999; Ancliff, Gale et al. 2001) without disrupting the 
enzymatic substrate cleavage by the active site.(Ancliff, Gale et al. 2001) The mutations seem 
to disturb a predicted transmembrane domain, leading to excessive granular accumulation 
of elastase and defective membrane localization of the enzyme.(Benson, Li et al. 2003) The 
myeloid precursors are characterized by cyclic increase in apoptosis.(Aprikyan, Kutyavin et 
al. 2003)  However, the precise molecular mechanism of the cycling hematopoiesis in the 
disease and why the same mutations in ELA2 are associated with both cyclic and 
Kostmann/severe congenital neutropenia phenotype are unknown. 
Myelokathexis is a rare autosomal dominant disorder with recurrent bacterial infections 
caused by reduced number and function of neutrophils.(Zuelzer 1964)  Neutropenia is 
typically moderate to severe. Degenerative changes in the granulocytes are characteristic 
and include pyknotic nuclear lobes, fine chromatin filaments and hypersegmentation. 
(Zuelzer 1964) Bone marrow specimens are usually hypercellular with granulocytic 
hyperplasia. The pathophysiology of myelokathexis has been attributed to a defective 
release of marrow cells into the peripheral blood.(Zuelzer 1964) Neutrophil precursors are 
characterized by depressed expression of BCL-X and accelerated apoptosis.(Aprikyan, Liles 
et al. 2000) G-CSF ameliorate the neutropenia and lead to clinical improvement during 
episodes of bacterial infection. (Zuelzer 1964; Wetzler, Talpaz et al. 1992) WHIM syndrome 
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refers to an association of myelokatheksis with other features (warts, 
hypogammaglobulinemia, infections and myelokalthexis). Most cases studied are caused by 
mutations in the chemokine receptor gene CXCR4. (Hernandez, Gorlin et al. 2003) The 
mutations result in enhanced chemotactic response of neutrophils in response to the CXCR4 
ligand CXCL12 (stroma-derived factor 1) and pathological retention of neutrophils in the 
bone marrow.(Gulino, Moratto et al. 2004) Patients with wild type CXCR4 might have other 
genetic defects that lead to enhanced interaction between CXCR4 and CXCL12 and 
enhanced chemotactic response, such as reduced inhibition of CXCL12-promoted 
internalization and desensitization of CXCR4 by GPCR kinase-3 due to decreased 
transcription of the GPCR kinase-3.(Balabanian, Levoye et al. 2008) 
Dursun syndrome is an autosomal recessive disorders with cardiac anomalies (particularly 
atrial septal defect), urogenital anomalies, vascular anomalies (prominent skin blood 
vessels), mild immune deficiency and intermittent mild thrombocytopenia.(Dursun, Ozgul 
et al. 2009) The bone marrow shows either normal maturation or promyelocyte-meylocyte 
arrest. The risk of MDS/AML is unknown. It is caused by mutation in G6PC3, the gene 
encodes for glucose-6-phosphatase catalytic unit 3.(Banka, Newman et al. ; Boztug, 
Appaswamy et al. 2009) G6PC3 is expressed ubiquitously. It is located in the endoplasmic 
reticulum and hydrolyses glucose-6-phosphate to glucose and phosphate. G6PC3 function 
loss causes impaired glucose recycling from the endoplasmic reticulum to the cytoplasm in 
neutrophils.(Jun, Lee et al.) Neutrophil endoplasmic reticulum stress increases susceptibility 
of neutrophils and myeloid cells to apoptosis,(Boztug, Appaswamy et al. 2009) possibly due 
to unfolded protein response as evident by enlarged rough endoplasmic reticulum and 
overexpression of BiP.(Cheung, Kim et al. 2007)  
Other disorders with isolated neutrophil production defects such as glycogen storage 
disease type Ib.(Annabi, Hiraiwa et al. 1998; Calderwood, Kilpatrick et al. 2001)and Barth 
syndrome (Bione, D'Adamo et al. 1996; Kuijpers, Maianski et al. 2004) are listed in Table 1. 
2.8 Selected other inherited bone marrow failure syndromes with predominantly 
anemia 
Congenital dyserythropoietic anemias (CDAs) are inherited disorders with prominent 
morphological dyserythropoiesis and ineffective erythropoiesis. Three main types of CDA 
exist: CDA I, II, and III, which differ in marrow morphology, serologic findings and 
inheritance patterns (Table 1). The anemia in most patients is not severe and does not 
mandate chronic therapy. In cases with severe anemia splenectomy, a chronic RBC 
transfusion program, or HSCT should be considered. Due to ineffective erythropoiesis and 
multiple transfusions, patients can develop iron overload necessitating iron chelation. CDAI 
is characterized by megaloblastic appearance of erythroid bone marrow precursors with 
some binucleated cells and internuclear chromatin bridges. The CDA I gene was identified 
as CDA1, which encodes for codanin-1. (Dgany, Avidan et al. 2002) The protein was shown 
and was entitled to be during cell cycle; it is localized to heterochromatin in interphase cells, 
overexpressed during the S phase and phosphorylated at mitosis. (Noy-Lotan, Dgany et al. 
2009) Another group found that codanin-1 interacts with HP1┙. Mutant codanin-1 results in 
abnormal accumulation of HP1┙ in the Golgi apparatus. (Renella, Roberts et al.)  CDA II is 
characterized by larger number of binucleated cells and some multinuclear cells. 
Abnormally high protein, lipid dysglycosylation and endoplasmic reticulum double-
membrane remnants are seen in erythroid cells. The gene for CDAII was identified as 
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SEC23B. The SEC23B protein is an essential component of protein complex II-coated vesicles 
that transport secretory proteins from the endoplasmic reticulum to the Golgi apparatus. 
Knockdown of SEC23B in zebrafish leads to aberrant erythrocyte development. The gene for 
CDA III has not been identified. 
Inherited sideroblastic anemias are disorders of mitochondrial iron utilization. Iron 
accumulation occurs in the mitochondria of red blood cell precursors. Perl’s Prussian-blue 
shows iron accumulation in a circular or ringed pattern around the nucleus in greater than 
10% of the erythroblasts. Treatment depends on the specific syndrome. Patients with X-
linked sideroblastic anemia respond to pyridoxine. Patients with thiamine responsive 
megaloblastic anemia respond to thiamine. In the other types of inherited sideroblastic 
anemia RBC transfusions are the mainstay of treatment. HSCT is curative.(Urban, Binder et 
al. 1992) The genes mutated in sideroblastic anemias are involved in heme biosynthesis, 
iron-sulfur cluster biogenesis, iron-sulfur cluster transport or mitochondrial metabolism 
(Table 1). 
2.9 Selected other inherited bone marrow failure syndromes with predominantly 
thrombocytopenia 
The syndrome of thrombocytopenia with absent radii (TAR) was first described in 
1929,(Greenwald and Sherman 1929) and subsequently defined in 1969,(Hall, Levin et al. 
1969) The two features, which are currently essential for the definition of the syndrome are 
hypomegakaryocytic thrombocytopenia and bilateral radial aplasia. The definition of the 
syndrome may change once the genetic basis is deciphered, and its inheritance mode may 
be clarified. Typically, parents of TAR syndrome patients are phenotypically normal, and 
females with TAR syndrome can conceive and give birth to hematologically and 
phenotypically normal offspring. Klopocki and colleagues reported deletion on 
chromosome 1q21.1 in TAR syndrome patients;(Klopocki, Schulze et al. 2007) however, the 
etiological significance of this finding is still unclear. Another group found that bone 
marrow adherent stromal cells from patients with TAR syndrome do not express CD105 
antigen, a protein component of the transforming growth factor-┚1 and ┚3 receptor complex 
which is normally expressed in mesenchymal cells.(Bonsi, Marchionni et al. 2009) They 
hypothesized that the clinical phenotype of TAR could derive from damage to a common 
osteo/chondrogenic and hematopoietic progenitors. 
MYH9-assocaited familial macrothrombocytopenia comprises an array of several 
syndromes; Alport, Fetchner, Ebstein, Sabastian and May-Hegglin, which have traditionally 
been classified according to their non-hematologtical manifestations.(Drachman 2004; 
Geddis and Kaushansky 2004). MYH9 encodes for nonmuscle myosin-heavy chain IIA, 
cytoskeletal contractile protein.(Seri, Pecci et al. 2003) The common features include 
autosomal dominant inheritance, large platelets, mild to moderated thrombocytopenia, 
normal numbers of megakaryocytes in the bone marrow and variable platelet aggregation 
and secretion defects which may rarely cause bleeding, requiring platelet 
transfusions.(Peterson, Rao et al. 1985) Progression into aplastic anemia or leukemia has not 
been reported thus far. Myosin-heavy chain IIA normally exists as a large hexamer, 
comprised of two heavy chains and 4 myosin light chains. The N-terminal head interacts 
with actin. An intermediate neck domain binds myosin light chains. Phosphorylation of 
myosin light chains result in activation of myosin and interaction with actin filaments. The 
C-terminal tail domain is important for filament assembly and cargo binding. Mutations in 
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the head region directly affect important functions of the motor protein and have a critical 
effect on function. Mutated myosin-heavy chain IIA light chains forms aggregates in 
neutrophils, which bind other proteins including normal myosin-heavy chain IIA from the 
normal allele. 
Familial non-syndromic thrombocytopenia is characterized by an autosomal dominant 
inheritance, mild to moderate thrombocytopenia, normal platelet size and morphology and 
mild bleeding tendency. There is no known increased risk of progression to leukemia. Bone 
marrow specimens are of normal cellularity with normal to mildly reduced numbers of 
megakaryocytes, which can be small and have hypolobulated nuclei. Clonogenic assays 
show increased megakaryocytic colony growth.(Drachman, Jarvik et al. 2000) Three genes 
have been reported as mutated in this disease (Table 1). The most common one is MASTL, 
which encodes for a putative kinase.(Gandhi, Cummings et al. 2003) MASTL expression is 
restricted to hematopoietic and cancer cell lines and localizes to the nucleus in 
overexpression studies.(Johnson, Gandhi et al. 2009) A transient knockdown of MASTL in 
zebrafish reduced platelet counts. 
Radioulnar synostosis with bone marrow failure is an autosomal dominant disorder with 
proximal radio-ulnar synostosis, clinodactyly, syndactyly, congenital hip dysplasia and 
sensorineural deafness.(Thompson, Woodruff et al. 2001) The thrombocytopenia can be 
severe and require platelet transfusions. The bone marrow shows absence of 
megakaryocytes. Progression into pancytopenia is common. If the thrombocytopenia is 
severe or progresses to aplastic anemia, allogeneic HSCT can be curative.(Thompson, 
Woodruff et al. 2001),(Castillo-Caro, Dhanraj et al.)   Most patients are heterozygous for 
mutations in the HOXA11 gene, which lead to truncation of the protein.(Thompson and 
Nguyen 2000) Some patients with classical presentation are negative for HOXA11.(Castillo-
Caro, Dhanraj et al.)  
Familial platelet disorder with predisposition to AML is an autosomal dominant disease and 
a striking predisposition for hematological malignancy.(Michaud, Wu et al. 2002) The 
thrombocytopenia is mild to moderate, and platelets have normal size and morphology. 
Treatment of the thrombocytopenia is usually not required, but periodic screening for 
pancytopenia and MDS/AML is advisable. HSCT is potentially curative in the leukemic 
phase. The disorder is caused by mutations in the RUNX1 gene.(Song, Sullivan et al. 1999) 
The thrombocytopenia may result from reduced MPL expression possibly by decreased 
binding of RUNX1 to the MPL promotor.(Heller, Glembotsky et al. 2005) RUNX1 acts as a 
tumor suppressor and promotes differentiation. 
Familial thrombocytopenia with dyserythropoiesis is an X-linked disease with mild to 
severe bleeding tendency and mild to moderate dyserythropoiesis.(Nichols, Crispino et al. 
2000; Mehaffey, Newton et al. 2001) Platelets are hypogranular and of normal-to large size. 
Platelet counts are moderately to severely affected (10-40 × 109/L), have variably low 
expression of glycoprotein Ib, and their aggregation in response to ristocitin is 
reduced.(Freson, Devriendt et al. 2001) The anemia is variable in severity. Bone marrow 
biopsy specimens are hypercellular with dysplastic megakaryocytes having peripheral 
location of the nucleus and lack of nuclear segmentation or fragmentation. Dysplastic 
erythroid precursors with mild megaloblastic changes and delayed nuclear maturation are 
also seen.(Mehaffey, Newton et al. 2001) There are no reports of progression to severe 
aplastic anemia, MDS or AML. The treatment consists of platelet transfusion in case of 
bleeding, trauma or preparation for surgery. Severe cases can be cured by allogeneic related 
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or unrelated HSCT.(Nichols, Crispino et al. 2000)  The disorder is caused by missense 
mutations in the GATA1 protein domain between 205-218 amino acids,(Nichols, Crispino et 
al. 2000) a transcription factor important for both magakaryopoiesis and erythropoiesis.  
Other IBMFSs with predominantly thrombocytopenia are listed in Table 1. 
3. Conclusion 
Multiple genes which function in many different pathways are associated with IBMFSs. 
However, about 45% of the patients do not have mutations in known genes; thus it is likely 
that many more genes remained to be identified. Despite accumulation of substantial 
knowledge about the functions of the IBMFS proteins, the mechanism of bone marrow 
failure in most of the conditions is still unknown.  
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